Abstract
SummaryThe new generation, i.e., second- and third-generation, drug-eluting stents (DESs) remain a risk of in-stent restenosis (ISR). We evaluated the power of a genetic risk score (GRS) model to identify high-risk populations for new generation DES ISR. We enrolled patients with coronary artery disease (CAD) treated with new generations DESs by a single-center cohort study in Taiwan and evaluated their genetic profile. After propensity score matching, there were 343 patients and 153 patients in the derivation and validation cohorts, respectively. Five selected single-nucleotide polymorphisms (SNPs), i.e., SNPs in CAMLG, GALNT2, C11orf84, THOC5, and SAMD11, were included to calculate the GRS for new generation DES ISR. In the derivation and the validation cohorts, patients with a GRS greater than or equal to 3 had significantly higher new generation DES ISR rates. We provide biological information for interventional cardiologists prior to percutaneous coronary intervention by specific five SNP-derived GRS.
Highlights
Coronary artery disease (CAD) has been the leading cause of mortality worldwide for decades
We evaluated the power of a genetic risk score (GRS) model to identify high-risk populations for new generation drug-eluting stents (DESs) in-stent restenosis (ISR)
We provide biological information for interventional cardiologists prior to percutaneous coronary intervention by specific five single-nucleotide polymorphisms (SNPs)-derived GRS
Summary
Coronary artery disease (CAD) has been the leading cause of mortality worldwide for decades. Because coronary artery stenosis is the most common cause of CAD, percutaneous coronary intervention (PCI) for angioplasty of the narrowing lesions has become a well-established therapeutic practice. Compared with balloon angioplasty and bare metal stent (BMS) deployment, drug-eluting stents (DESs) significantly reduce the incidence of restenosis and improve patient prognosis (Bonaa et al, 2016). Owing to improvements in stent design, drugs and polymers of DESs, and application of intracoronary imaging modalities during PCI, the in-stent restenosis (ISR) rate of the new generation DES, i.e., second- and third-generation DESs, is very low (Bonaa et al, 2016; Shlofmitz et al, 2019; Piccolo et al, 2015). New generation DES ISR remains a clinical challenge
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
